Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation

Avitinib is well tolerated and efficacious in T790M-positive patients. Its penetrability to the BBB is weak, but it showed good control of asymptomatic brain metastases. Further studies are proceeding.